Search

Author/Creator Gericke, Germo

1. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Issue 12 (December 2021)

Authors:
Strosberg, Jonathan R; Caplin, Martyn E; Kunz, Pamela L; Ruszniewski, Philippe B; Bodei, Lisa; Hendifar, Andrew; Mittra, Erik; Wolin, Edward M; Yao, James C; Pavel, Marianne E; Grande, Enrique; Van Cutsem, Eric; Seregni, Ettore; Duarte, Hugo; Gericke, Germo; Bartalotta, Amy; Mariani, Maurizio F; ...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 12(2021)
Page Start:
1752
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search